Fractyl Health (GUTS) Set to Announce Earnings on Tuesday

Fractyl Health (NASDAQ:GUTS - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.10. The firm had revenue of $0.04 million during the quarter. On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fractyl Health Stock Performance

GUTS stock traded down $0.16 on Tuesday, hitting $2.40. 589,937 shares of the company's stock traded hands, compared to its average volume of 315,561. Fractyl Health has a 1-year low of $1.74 and a 1-year high of $14.50. The stock has a fifty day moving average of $2.75 and a 200-day moving average of $4.23. The company has a quick ratio of 7.46, a current ratio of 7.46 and a debt-to-equity ratio of 0.40.

Insider Transactions at Fractyl Health

In other Fractyl Health news, insider Jay David Caplan sold 65,000 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $2.90, for a total value of $188,500.00. Following the completion of the sale, the insider now directly owns 30,484 shares of the company's stock, valued at $88,403.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.